Tonix Pharmaceuticals Holding Corporation (TNXP) Actualités

Tonix Pharmaceuticals to Present at the 2025 Virtual Investor Summit

CHATHAM, N.J., March 05, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix...

Form 8-K - Current report

Form 8-K - Current report

Tonix Pharmaceuticals Presented Data and Analyses of TNX-102 SL Treatment Effects on Fibromyalgia at 7th International Congress on Controversies in Fibromyalgia

TNX-102 SL is a sublingual formulation of cyclobenzaprine designed for transmucosal delivery and durable...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Form 3 - Initial statement of beneficial ownership of securities

Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]

Form 8-K - Current report

Tonix Pharmaceuticals Recently Announced Preliminary Full Year 2024 Operating Results and Year-End Cash

Company had $98.8 million in cash as of December 31, 2024; existing cash expected to fund planned operations...

Form 8-K - Current report